Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jedd Wolchok

Showing results (21-30 of 38) with videos related to

Pageof 4
Sort By:
Cancer Immunology Research|January 21, 2015
Requirement for innate immunity and CD90⁺ NK1.1⁻ lymphocytes to treat established melanoma with chemo-immunotherapyMarina Moskalenko, Michael Pan, Yichun Fu, et al.
The Journal of Clinical Investigation|June 15, 2011
Multimodal silica nanoparticles are effective cancer-targeted probes in a model of human melanomaMiriam Benezra, Oula Penate-Medina, Pat B Zanzonico, et al.
Melanoma Research|January 23, 2016
A phase 2 trial of everolimus and pasireotide long-acting release in patients with metastatic uveal melanomaAlexander N Shoushtari, Leonard T Ong, Heiko Schoder, et al.
Journal for Immunotherapy of Cancer|November 20, 2021
Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067Meredith M Regan, Charlene M Mantia, Lillian Werner, et al.
Oncotarget|June 22, 2016
The metabolic/pH sensor soluble adenylyl cyclase is a tumor suppressor proteinLavoisier Ramos-Espiritu, Ana Diaz, Charlee Nardin, et al.
Journal for Immunotherapy of Cancer|November 18, 2021
Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational studyFangwen Zou, David Faleck, Anusha Thomas, et al.
Journal for Immunotherapy of Cancer|January 25, 2022
Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analysesClaire F Friedman, Christine Spencer, Christopher R Cabanski, et al.
Kidney International|June 11, 2016
Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitorsFrank B Cortazar, Kristen A Marrone, Megan L Troxell, et al.
European Journal of Cancer (Oxford, England : 1990)|June 27, 2017
Health-related quality of life results from the phase III CheckMate 067 studyDirk Schadendorf, James Larkin, Jedd Wolchok, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|March 2, 2017
Patient perspectives on ipilimumab across the melanoma treatment trajectoryElyse Shuk, Alexander N Shoushtari, Jason Luke, et al.
Pageof 4

Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
Cancer Immunology Research|January 21, 2015
Requirement for innate immunity and CD90⁺ NK1.1⁻ lymphocytes to treat established melanoma with chemo-immunotherapyMarina Moskalenko, Michael Pan, Yichun Fu, et al.
The Journal of Clinical Investigation|June 15, 2011
Multimodal silica nanoparticles are effective cancer-targeted probes in a model of human melanomaMiriam Benezra, Oula Penate-Medina, Pat B Zanzonico, et al.
Melanoma Research|January 23, 2016
A phase 2 trial of everolimus and pasireotide long-acting release in patients with metastatic uveal melanomaAlexander N Shoushtari, Leonard T Ong, Heiko Schoder, et al.
Journal for Immunotherapy of Cancer|November 20, 2021
Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067Meredith M Regan, Charlene M Mantia, Lillian Werner, et al.
Oncotarget|June 22, 2016
The metabolic/pH sensor soluble adenylyl cyclase is a tumor suppressor proteinLavoisier Ramos-Espiritu, Ana Diaz, Charlee Nardin, et al.
Journal for Immunotherapy of Cancer|November 18, 2021
Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational studyFangwen Zou, David Faleck, Anusha Thomas, et al.
Journal for Immunotherapy of Cancer|January 25, 2022
Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analysesClaire F Friedman, Christine Spencer, Christopher R Cabanski, et al.
Kidney International|June 11, 2016
Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitorsFrank B Cortazar, Kristen A Marrone, Megan L Troxell, et al.
European Journal of Cancer (Oxford, England : 1990)|June 27, 2017
Health-related quality of life results from the phase III CheckMate 067 studyDirk Schadendorf, James Larkin, Jedd Wolchok, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|March 2, 2017
Patient perspectives on ipilimumab across the melanoma treatment trajectoryElyse Shuk, Alexander N Shoushtari, Jason Luke, et al.
Pageof 4